Vaccines, Adjuvants, and Dendritic Cell Activators - Current Status and Future Challenges

Seminars in Oncology

Volumn 42, Issue 4, 2015, Pages 549-561

  Obeid, Joseph ^a   Hu, Yinin ^a   Slingluff, Craig L ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CD19 ANTIGEN; CETUXIMAB; DENDRITIC CELL VACCINE; DNA VACCINE; GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOLOGICAL ADJUVANT; MELAN A; MESOTHELIN; NELIPEPIMUT S; RINDOPEPIMUT; RNA VACCINE; SIPULEUCEL T; TALIMOGENE LAHERPAREPVEC; TRASTUZUMAB;

ANTIGEN EXPRESSION; ARTICLE; BRAIN TUMOR; CANCER IMMUNOTHERAPY; CELL ACTIVATION; DENDRITIC CELL; HUMAN; INNATE IMMUNITY; MELANOMA; MONOTHERAPY; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; PROSTATE CANCER; TISSUE DIFFERENTIATION; TUMOR MICROENVIRONMENT; ACTIVE IMMUNIZATION; IMMUNOLOGY; NEOPLASMS; PREVENTION AND CONTROL; PROCEDURES; TUMOR RECURRENCE;

ADJUVANTS, IMMUNOLOGIC; CANCER VACCINES; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY, ACTIVE; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS;

EID: 84940371965     PISSN: 00937754     EISSN: 15328708     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2015.05.006     Document Type: Review

References (102)

1. C. Denkert, M.G. von, J.C. Brase, and et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemorapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers J Clin Oncol 33 2015 983 991
2. J. Galon, A. Costes, F. Sanchez-Cabo, and et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome Science 313 2006 1960 1964
3. G. Erdag, J.T. Schaefer, M.E. Smolkin, and et al. Immunotype and immunohistologic characteristics of tumor infiltrating immune cells are associated with clinical outcome in metastatic melanoma Cancer Res 72 2012 1070 1080
4. B. Clarke, A.V. Tinker, C.H. Lee, and et al. Intraepilial T cells and prognosis in ovarian carcinoma: Novel associations with stage, tumor type, and BRCA1 loss Mod Pathol 22 2009 393 402
5. P. Agarwalla, Z. Barnard, P. Fecci, G. Dranoff, and W.T. Curry Jr Sequential immunorapy by vaccination with GM-CSF-expressing glioma cells and CTLA-4 blockade effectively treats established murine intracranial tumors J Immunor 35 2012 385 389
6. L.V. Ly, M. Sluijter, M. Versluis, and et al. Peptide vaccination after T-cell transfer causes massive clonal expansion, tumor eradication, and manageable cytokine storm Cancer Res 70 2010 8339 8346
7. Y. Lou, G. Wang, G. Lizee, and et al. Dendritic cells strongly boost anti-tumor activity of adoptively transferred T cells in vivo Cancer Res 64 2004 6783 6790
8. C.S. Higano, P.F. Schellhammmer, E.J. Small, and et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunorapy with sipuleucel-T in advanced prostate cancer Cancer 115 2009 3670 3679
9. C.L. Slingluff Jr, G.R. Petroni, K.A. Chianese-Bullock, and et al. Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in adjuvant setting Clin Cancer Res 13 2007 6386 6395
10. S.A. Rosenberg, R.M. Sherry, K.E. Morton, and et al. Tumor progression can occur despite induction of very high levels of self/tumor antigen-specific CD8+T cells in patients with melanoma J Immunol 175 2005 6169 6176
11. S.A. Rosenberg, J.C. Yang, and N.P. Restifo Cancer immunorapy: moving beyond current vaccines Nat Med 10 2004 909 915
12. D.J. Schwartzentruber, D.H. Lawson, J.M. Richards, and et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma N Engl J Med 364 2011 2119 2127
13. G.G. Kenter, M.J. Welters, A.R. Valentijn, and et al. Vaccination against HPV-16 oncoproteins for vulvar intraepilial neoplasia N Engl J Med 361 2009 1838 1847
14. D.T. Le, A. Wang-Gillam, V. Picozzi, and et al. Safety and survival with GVAX pancreas prime and listeria monocytogenes-expressing mesolin (CRS-207) boost vaccines for metastatic pancreatic cancer J Clin Oncol 33 2015 1325 1333
15. A.M. Swartz, Q.J. Li, and J.H. Sampson Rindopepimut: A promising immunorapeutic for treatment of glioblastoma multiforme Immunorapy 6 2014 679 690
16. J. Schuster, R.K. Lai, L.D. Recht, and et al. A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: ACT III study Neurooncol 17 2015 854 861
17. E.A. Mittendorf, G.T. Clifton, J.P. Holmes, and et al. Clinical trial results of HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: From US Military Cancer Institute Clinical Trials Group Study I-01 and I-02 Cancer 118 2012 2594 2602
18. M.G. Carmichael, L.C. Benavides, J.P. Holmes, and et al. Results of first phase 1 clinical trial of HER-2/neu peptide (GP2) vaccine in disease-free breast cancer patients: United States Military Cancer Institute Clinical Trials Group Study I-04 Cancer 116 2010 292 301
19. H.L. Kaufman, and S.D. Bines OPTIM trial: A Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma Future Oncol 6 2010 941 949
20. S. Walter, T. Weinschenk, C. Reinhardt, and H. Singh-Jasuja Single-dose cyclophosphamide synergizes with immune responses to renal cell cancer vaccine IMA901 Oncoimmunology 2 2013 e22246
21. S.W.T. Walter, A. Stenzl, and et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival Nat Med 18 2012 1254 1261
22. GlaxoSmithKline. Update on phase III clinical trial of investigational MAGE-A3 antigen-specific cancer immunorapeutic in non-small cell lung cancer. 4-2-2014. 1-4-2015. Http://us.gsk.com/en-us/media/press-releases/2014/update-on-phase-iii-clinical-trial-of-investigational-mage-a3-antigen-specific-cancer-immunorapeutic-in-non-small-cell-lung-cancer/
23. W.H. Kruit, S. Suciu, B. Dreno, and et al. Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma J Clin Oncol 31 2013 2413 2420
24. W.H. Kruit, S. Suciu, B. Dreno, and et al. Immunization with recombinant MAGE-A3 protein combined with adjuvant systems AS15 or AS02B in patients with unresectable and progressive metastatic cutaneous melanoma: A randomized open-label phase II study of EORTC Melanoma Group (16032-18031) J Clin Oncol 2008 26 abstract 9065
25. J. Louahed, O. Gruselle, S. Gaulis, and et al. Expression of defined genes identified by pretreatment tumor profiling: Association with clinical responses to GSK MAGE-A3 immunorapeutic in metastatic melanoma patients (16032- 18031) J Clin Oncol 2008 26 abstract 9045
26. J.L. Gulley, R.A. Madan, K.Y. Tsang, and et al. Immune impact induced by PROSTVAC (PSA-TRICOM), a rapeutic vaccine for prostate cancer Cancer Immunol Res 2 2014 133 141
27. P.W. Kantoff, T.J. Schuetz, B.A. Blumenstein, and et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunorapy in metastatic castration-resistant prostate cancer J Clin Oncol 28 2010 1099 1105
28. Glaxo Smith Kline. investigational MAGE-A3 antigen-specific cancer immunorapeutic does not meet first co-primary endpoint in phase III melanoma clinical trial. 9-5-2013. Http://www.gsk.com/en-gb/media/press-releases/2013/-investigational-mage-a3-antigen-specific-cancer-immunorapeutic-does-not-meet-first-co-primary-endpoint-in-phase-iii-melanoma-clinical-trial/.
29. L.A. Johnson, R.A. Morgan, M.E. Dudley, and et al. Gene rapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen Blood 114 2009 535 546
30. G.L. Beatty, A.R. Haas, M.V. Maus, and et al. Mesolin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies Cancer Immunol Res 2 2014 112 120
31. R.A. Henderson, W.M. Konitsky, S.M. Barratt-Boyes, M. Soares, P.D. Robbins, and O.J. Finn Retroviral expression of MUC-1 human tumor antigen with intact repeat structure and capacity to elicit immunity in vivo J Immunor 21 1998 247 256
32. A.E. Siroy, G.M. Boland, D.R. Milton, and et al. Beyond BRAF(V600): Clinical mutation panel testing by next-generation sequencing in advanced melanoma J Invest Dermatol 135 2015 508 515
33. E.F. Fritsch, M. Rajasagi, P.A. Ott, V. Brusic, N. Hacohen, and C.J. Wu HLA-binding properties of tumor neoepitopes in humans Cancer Immunol Res 2 2014 522 529
34. G.M. Heestand, and R. Kurzrock Molecular landscape of pancreatic cancer: implications for current clinical trials Oncotarget 10 2015 4553 4561
35. P.F. Robbins, M. el-Gamil, Y.F. Li, E.B. Fitzgerald, Y. Kawakami, and S.A. Rosenberg intronic region of an incompletely spliced gp100 gene transcript encodes an epitope recognized by melanoma-reactive tumor-infiltrating lymphocytes J Immunol 159 1997 303 308
36. M. Fijak, S. Bhushan, and A. Meinhardt Immunoprivileged sites: Testis Methods Mol Biol 677 2011 459 470
37. M.F. Gjerstorff, J. Burns, and H.J. Ditzel Cancer-germline antigen vaccines and epigenetic enhancers: Future strategies for cancer treatment Expert Opin Biol r 10 2010 1061 1075
38. P.F. Robbins, R.A. Morgan, S.A. Feldman, and et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1 J Clin Oncol 29 2011 917 924
39. R.A. Morgan, N. Chinnasamy, D. Abate-Daga, and et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene rapy J Immunor 36 2013 133 151
40. M. Cobbold, H. De La Pena, A. Norris, and et al. MHC class I-associated phosphopeptides are targets of memory-like immunity in leukemia Sci Transl Med 5 2013 203ra125
41. F.R. Depontieu, J. Qian, A.L. Zarling, and et al. Identification of tumor-associated, MHC class II-restricted phosphopeptides as targets for immunorapy Proc Natl Acad Sci U S A 106 2009 12073 12078
42. Y.C. Lu, X. Yao, J.S. Crystal, and et al. Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions Clin Cancer Res 20 2014 3401 3410
43. Y.C. Lu, X. Yao, Y.F. Li, and et al. Mutated PPP1R3B is recognized by T cells used to treat a melanoma patient who experienced a durable complete tumor regression J Immunol 190 2013 6034 6042
44. A.S. Charen, V. Makarov, T. Merghoub, and et al. neoantigen landscape underlying clinical response to ipilimumab J Clin Oncol (Meeting Abstracts) 2014 32 abstract 3003
45. N. van Rooij, M.M. van Buuren, D. Philips, and et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma J Clin Oncol 31 2013 e439 e442
46. E. Zorn, and T. Hercend A natural cytotoxic T cell response in a spontaneously regressing human melanoma targets a neoantigen resulting from a somatic point mutation Eur J Immunol 29 1999 592 601
47. H. Matsushita, M.D. Vesely, D.C. Koboldt, and et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting Nature 482 2012 400 404
48. M. Tagliamonte, A. Petrizzo, M.L. Tornesello, F.M. Buonaguro, and L. Buonaguro Antigen-specific vaccines for cancer treatment Hum Vaccin Immunor 10 2014 3332 3346
49. F. Aranda, E. Vacchelli, A. Eggermont, and et al. Trial Watch: Peptide vaccines in cancer rapy Oncoimmunology 2 2013 e26621
50. + T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial Clin Cancer Res 15 2009 7036 7044
51. C.L. Slingluff Jr present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination? Cancer J 17 2011 343 350
52. M. Noguchi, G. Arai, K. Matsumoto, and et al. Phase I trial of a cancer vaccine consisting of. 20 mixed peptides in patients with castration-resistant prostate cancer: dose-related immune boosting and suppression Cancer Immunol Immunor 64 2015 493 505
53. L.H. Brinckerhoff, V.V. Kalashnikov, L.W. Thompson, and et al. Terminal modifications inhibit proteolytic degradation of an immunogenic MART-1(27-35) peptide: implications for peptide vaccines Int J Cancer 83 1999 326 334
54. K.L. Knutson, K. Schiffman, M.A. Cheever, and M.L. Disis Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity Clin Cancer Res 8 2002 1014 1018
55. C.J. Melief, and S.H. van der Burg Immunorapy of established (pre)malignant disease by syntic long peptide vaccines Nat Rev Cancer 8 2008 351 360
56. M.S. Bijker, S.J. van den Eeden, K.L. Franken, C.J. Melief, S.H. van der Burg, and R. Offringa Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation Eur J Immunol 38 2008 1033 1042
57. P. Sabbatini, T. Tsuji, L. Ferran, and et al. Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients Clin Cancer Res 18 2012 6497 6508
58. P.M. Dillon, W.C. Olson, A. Czarkowski, and et al. A melanoma helper peptide vaccine increases Th1 cytokine production by leukocytes in peripheral blood and immunized lymph nodes J Immunor Cancer 2 2014 23
59. C.L. Slingluff Jr, G.R. Petroni, W. Olson, and et al. Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens J Clin Oncol 26 2008 4973 4980
60. Y. Hu, G.R. Petroni, W.C. Olson, and et al. Immunologic hierarchy, class II MHC promiscuity, and epitope spreading of a melanoma helper peptide vaccine Cancer Immunol Immunor 63 2014 779 786
61. C.L. Slingluff Jr, G.R. Petroni, K.A. Chianese-Bullock, and et al. A randomized multicenter trial of effects of melanoma-associated helper peptides and cyclophosphamide on immunogenicity of a multipeptide melanoma vaccine J Clin Oncol 29 2011 2924 2932
62. C.L. Slingluff Jr, S. Lee, F. Zhao, and et al. A randomized phase II trial of multi-epitope vaccination with melanoma peptides for cytotoxic T-cells and helper T-cells for patients with metastatic melanoma (E1602) Clin Cancer Res 19 2013 4228 4238
63. L. Senovilla, E. Vacchelli, P. Garcia, and et al. Trial watch: DNA vaccines for cancer rapy Oncoimmunology 2 2013 e23803
64. V. Boisguerin, J.C. Castle, M. Loewer, and et al. Translation of genomics-guided RNA-based personalised cancer vaccines: Towards bedside Br J Cancer 111 2014 1469 1475
65. C.H. Chen, T.L. Wang, C.F. Hung, and et al. Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene Cancer Res 60 2000 1035 1042
66. D.A. Grosenbaugh, A.T. Leard, P.J. Bergman, and et al. Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of primary tumor Am J Vet Res 72 2011 1631 1638
67. J.H. van den Berg, K. Oosterhuis, T.N. Schumacher, J.B. Haanen, and A.D. Bins Intradermal vaccination by DNA tattooing Methods Mol Biol 1143 2014 131 140
68. L.M. Wood, and Y. Paterson Attenuated Listeria monocytogenes: A powerful and versatile vector for future of tumor immunorapy Front Cell Infect Microbiol 4 2014 51
69. J. Ozao-Choy, D.J. Lee, and M.B. Faries Melanoma vaccines: mixed past, promising future Surg Clin North Am 94 2014 1017 1030
70. J.C. Bystryn, A. Zeleniuch-Jacquotte, R. Oratz, R.L. Shapiro, M.N. Harris, and D.F. Roses Double-blind trial of a polyvalent, shed-antigen, melanoma vaccine Clin Cancer Res 7 2001 1882 1887
71. A. Testori, J. Richards, E. Whitman, and et al. Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: C-100-21 Study Group J Clin Oncol 26 2008 955 962
72. J.A. Sosman, J.M. Unger, P.Y. Liu, and et al. Adjuvant immunorapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome J Clin Oncol 20 2002 2067 2075
73. D.L. Morton, N. Mozzillo, J.F. Thompson, and et al. An international, randomized, phase III trial of bacillus Calmette-Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites J Clin Oncol Annual Meeting Proceedings Part I 2007 25 abstract 8508
74. N. Woller, E. Gurlevik, C.I. Ureche, A. Schumacher, and F. Kuhnel Oncolytic viruses as anticancer vaccines Front Oncol 4 2014 188
75. N.B. Elsedawy, and S.J. Russell Oncolytic vaccines Expert Rev Vaccines 12 2013 1155 1172
76. I. Puzanov, M. Milhem, R.H. Andtbacka, and et al. Primary analysis of a phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma J Clin Oncol 2014 32 abstract 9029
77. Y.H. Kim, D. Gratzinger, C. Harrison, and et al. In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: A phase 1/2 study Blood 119 2012 355 363
78. M.J. Goldstein, B. Varghese, J.D. Brody, and et al. A CpG-loaded tumor cell vaccine induces anti-tumor CD4+T cells that are effective in adoptive rapy for large and established tumors Blood 117 2011 118 127
79. A.M. Salazar, R.B. Erlich, A. Mark, N. Bhardwaj, and R.B. Herberman rapeutic in situ autovaccination against solid cancers with intratumoral poly-ICLC: Case report, hyposis, and clinical trial Cancer Immunol Res 2 2014 720 724
80. C.L. Slingluff Jr, G.R. Petroni, G.V. Yamshchikov, and et al. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides eir administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells J Clin Oncol 21 2003 4016 4026
81. D.W. O'Neill, S. Adams, J.D. Goldberg, and et al. Comparison of immunogenicity of Montanide ISA 51 adjuvant and cytokine-matured dendritic cells in a randomized controlled clinical trial of melanoma vaccines J Clin Oncol (Meeting Abstracts) 2009 27 abstract 3002
82. Y.T. Lim Vaccine adjuvant materials for cancer immunorapy and control of infectious disease Clin Exp Vaccine Res 4 2015 54 58
83. D.J. Marciani Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity Drug Discov Today 8 2003 934 943
84. J. Freund, and K.J. Thomson A simple, rapid technic of preparing water-in-oil emulsions of penicillin, drugs and biologics Science 101 1945 468 469
85. Y. Hailemichael, Z. Dai, N. Jaffarzad, and et al. Persistent antigen at vaccination sites induces tumor-specific CD8(+) T cell sequestration, dysfunction and deletion Nat Med 19 2013 465 472
86. J.T. Schaefer, J.W. Patterson, D.H. Deacon, and et al. Dynamic changes in cellular infiltrates with repeated cutaneous vaccination: A histologic and immunophenotypic analysis J Translat Med 8 2010 79
87. E.P. Salerno, S.M. Shea, W.C. Olson, and et al. Activation, dysfunction and retention of T cells in vaccine sites after injection of incomplete Freund's adjuvant, with or without peptide Cancer Immunol Immunor 62 2013 1149 1159
88. T.W. Dubensky Jr, D.B. Kanne, and M.L. Leong Rationale, progress and development of vaccines utilizing STING-activating cyclic dinucleotide adjuvants r Adv Vaccines 1 2013 131 143
89. P. Lee, F. Wang, J. Kuniyoshi, and et al. Effects of interleukin-12 on immune response to a multipeptide vaccine for resected metastatic melanoma J Clin Oncol 19 2001 3836 3847
90. H.L. Kaufman, C.E. Ruby, T. Hughes, and C.L. Slingluff Jr Current status of granulocyte-macrophage colony-stimulating factor in immunorapy of melanoma J Immunor Cancer 2 2014 11
91. G. Dranoff, E. Jaffee, A. Lazenby, and et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity Proc Natl Acad Sci U S A 90 1993 3539 3543
92. J.D. Ahlers, N. Dunlop, D.W. Alling, P.L. Nara, and J.A. Berzofsky Cytokine-in-adjuvant steering of immune response phenotype to HIV-1 vaccine constructs: granulocyte-macrophage colony-stimulating factor and TNF-alpha synergize with IL-12 to enhance induction of cytotoxic T lymphocytes J Immunol 158 1997 3947 3958
93. F.S. Hodi, S. Lee, D.F. McDermott, and et al. Ipilimumab plus sargramostim v ipilimumab alone for treatment of metastatic melanoma: A randomized clinical trial JAMA 312 2014 1744 1753
94. L.A. Emens, J.M. Asquith, J.M. Learman, and et al. Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: A chemorapy dose-ranging factorial study of safety and immune activation J Clin Oncol 27 2009 5911 5918
95. K. Barrios, and E. Celis TriVax-HPV: An improved peptide-based rapeutic vaccination strategy against human papillomavirus-induced cancers Cancer Immunol Immunor 61 2012 1307 1317
96. F.S. Hodi, S.J. O'Day, D.F. McDermott, and et al. Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 2010 711 723
97. V.K. Sondak, P.Y. Liu, R.J. Tuthill, and et al. Adjuvant immunorapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of Southwest Oncology Group J Clin Oncol 20 2002 2058 2066
98. M.B. Faries, E.C. Hsueh, X. Ye, M. Hoban, and D.L. Morton Effect of granulocyte/macrophage colony-stimulating factor on vaccination with an allogeneic whole-cell melanoma vaccine Clin Cancer Res 15 2009 7029 7035
99. D.S. Chen, and I. Mellman Oncology meets immunology: Cancer-immunity cycle Immunity 39 2013 1 10
100. G.R. Weiss, W.W. Grosh, K.A. Chianese-Bullock, and et al. Molecular insights on peripheral and intratumoral effects of systemic high-dose rIL-2 (aldesleukin) administration for treatment of metastatic melanoma Clin Cancer Res 17 2011 7440 7450
101. F. Ulloa-Montoya, J. Louahed, B. Dizier, and et al. Predictive gene signature in MAGE-A3 antigen-specific cancer immunorapy J Clin Oncol 31 2013 2388 2395
102. S.A. Grupp, M. Kalos, D. Barrett, and et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia N Engl J Med 368 2013 1509 1518